Cargando…
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
BACKGROUND: The purpose of this study was to identify a real-world US population having undergone surgery for malignant melanoma and describe treatment patterns, health care resource utilization, and costs for patients who subsequently received interferon alfa-2b (IFN) therapy or other standard of c...
Autores principales: | Hackshaw, Michelle D, Krishna, Arun, Mauro, David J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385977/ https://www.ncbi.nlm.nih.gov/pubmed/22754281 http://dx.doi.org/10.2147/CEOR.S32349 |
Ejemplares similares
-
Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009) -
Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021) -
Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
por: Zhang, Ying, et al.
Publicado: (2015) -
Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
por: Ashraf, Farhan, et al.
Publicado: (2016) -
Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)